Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 avr. 2026 01h00 HE | Source: Sanofi Winthrop Industrie

Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Phase 2 studies of lunsekimig, a novel bispecific nanobody, met primary and key secondary endpoints in two chronic respiratory conditions.
06 avr. 2026 09h00 HE | Source: Flare Therapeutics Inc.

Flare Therapeutics Announces Three Upcoming Poster Presentations at AACR Annual Meeting 2026

CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for...
06 avr. 2026 09h00 HE | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an...
06 avr. 2026 08h00 HE | Source: Avalyn Pharma Inc.

Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors

BOSTON, April 06, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment...
06 avr. 2026 08h00 HE | Source: Tenvie Therapeutics, Inc.

Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor

First candidate from Tenvie’s product engine to enter clinical developmentPhase 1 first-in-human study to evaluate single and multiple ascending doses of TNV262 in healthy volunteers and persons with...
06 avr. 2026 07h30 HE | Source: Medicus Pharma Ltd

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

PHILADELPHIA, April 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...
03 avr. 2026 17h00 HE | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on April 2, 2026, it received a notice (the “Notice”)...
03 avr. 2026 08h00 HE | Source: MBX Biosciences, Inc.

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel...
02 avr. 2026 17h05 HE | Source: Barrick Mining Corporation

Barrick Provides an Update on Reko Diq

All amounts expressed in U.S. dollars TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Barrick Mining Corporation (NYSE:B)(TSX:ABX) (“Barrick” or the “Company”) today provides an update on the status of...
02 avr. 2026 12h30 HE | Source: GENFIT S.A.

GENFIT : Résultats financiers annuels 2025 et point sur les activités de la Société

Faits financiers marquants de 2025 : Trésorerie et équivalents de trésorerie s’élevant à 101.1 millions d’euros au 31 décembre 2025 Chiffre d’affaires s’élevant à 65.4 millions d’euros au 31 décembre...

Page précédente

Page suivante